ArticleJAC-antimicrobial resistance2020
Evaluation of Vitek®2 performance for colistin susceptibility testing for Gram-negative isolates.
Article in JAC-antimicrobial resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Prevalence of colistin-resistant Enterobacteriaceae isolated from clinical samples in Africa: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- A Performance Evaluation of the VitekAntibiotics (Basel, Switzerland) · 2026Article
- Artificial Intelligence for Antimicrobial Resistance Detection and Prediction inInfection and drug resistance · 2026Review
- Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli.Microbiology spectrum · 2025Article
- Article
- Targeted 'knock out' therapy with a combination antimicrobial regimen restores treatment options in the management of extensively drug-resistant carbapenemase-producing organisms.Journal of medical microbiology · 2025Article
- Clinical and microbiological analyses of colistin-resistant strains among carbapenem-resistantMicrobiology spectrum · 2025Article
- Article
- Genome analyses of colistin-resistant high-risk blaBMC microbiology · 2024Article
- Genomic and phenotypic inconsistencies inFrontiers in cellular and infection microbiology · 2024Observational
- Article
- High-level Colonization With Antibiotic-Resistant Enterobacterales Among Individuals in a Semi-Urban Setting in South India: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Prevalence of Colonization With Antibiotic-Resistant Organisms in Hospitalized and Community Individuals in Bangladesh, a Phenotypic Analysis: Findings From the Antibiotic Resistance in Communities and Hospitals (ARCH) Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Outbreak report of polymyxin-carbapenem-resistant Klebsiella pneumoniae causing untreatable infections evidenced by synergy tests and bacterial genomes.Scientific reports · 2023Article
- Antibiotic Susceptibility Testing (AST) Practices in India: Need for a National AST Forum.Cureus · 2022Article
- Distribution and Genomic Characterization of Third-Generation Cephalosporin-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Performance Evaluation of the VITEK2 and Sensititre Systems to Determine Colistin Resistance and MIC forDiagnostics (Basel, Switzerland) · 2022Article
- Comparison of Six Phenotypic Assays with Reference Methods for Assessing Colistin Resistance in Clinical Isolates of Carbapenemase-Producing Enterobacterales: Challenges and Opportunities.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe emerging resistance to the last-resort antimicrobial colistin is being reported globally. Underestimation of the burden of colistin resistance and misinterpretation of colistin susceptibility test results, using suboptimal testing methods, may be causing unexplained treatment failures and even mortality among critically ill patients. Thus, this study was conducted at an apex trauma centre to assess the performance of Vitek®2 for colistin susceptibility testing.
methodsA total of 910 clinical isolates of Gram-negative bacteria (GNB), including Enterobacterales,
resultsA total of 64% of isolates were MDR. Overall, 196 (21.5%) and 110 (12%) of isolates were resistant to colistin by BMD and Vitek®2, respectively. The automated Vitek®2 method failed to detect the resistance in up to 48.5% of GNB tested. When comparing Vitek®2 colistin interpretive results with reference BMD for all 910 isolates, the CA was 88% (798/910) with 10% (95/910) VMEs and 1% (9/910) MEs.
conclusionsThe Vitek®2 method for colistin susceptibility testing, still in use in some settings; is a suboptimal and unreliable method.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.